Intense efforts have been made to inhibit the activities of the ERBB1/EGFR and ERBB2/HER2 receptors in cancer patients by designing antibodies against the ligand binding domains or small molecules against the tyrosine kinase domains. Here, ERBB2 is linked to cancer.